

# A Pharmacoeconomic Comparison of Antihypertensive Efficacy of Beta Blockers

Bharti Sharma

University School of Pharmaceutical Sciences, Rayat and Bahra University, Mohali, India

**Abstract:** *The cost-viability of the treatment of hypertension has barely been explored in population based investigations. Most information originates from optional examination of clinical preliminaries and regulatory sources. Due to the high rate of grimness and mortality related with hypertension in the older, the treatment of hypertension in this patient gathering must include thought of clinical, humanistic and monetary results. The most of the time utilized technique for pharmacoeconomic investigation for antihypertensive treatment includes cost-viability examination, albeit a few different strategies are accessible. Current proof uncovers a pattern toward cost viability of antihypertensive treatment in old patients. Not with standing, these formal examinations are constrained by the requirement for extrapolation of information with respect to adequacy and dimension of hazard from epidemiological and randomized preliminaries, data which is regularly deficient. To join financial variables into clinical basic leadership, different proportions of monetary effect ought to be investigated. The monetary effect of antihypertensive treatment is influenced by the dimension of hazard for the patient and the viability of the treatment. Information show that the danger of horribleness and mortality identified with hypertension increments with age and that present antihypertensive medications decrease this hazard. While picking an antihypertensive specialist, the accompanying parameters ought to be considered: securing cost, probability of unfriendly impacts and different determinants of treatment adherence, and individual indicators of reaction. The financial results will be boosted if judicious medication choice is enhanced by proper demonstrative and grouping techniques and decrease of cardiovascular hazard factors other than hypertension. The aggregation of information tending to the dangers and advantages of treatment for the extremely old and the near adequacy of more up to date antihypertensive treatments will additionally clear up the basic leadership process. **Title:** Pharmacoeconomic comparison of efficacy of two antihypertensive beta blockers: cost-effectiveness analysis of nebivolol and metoprolol in essential hypertension **Objective:** To compare the effectiveness of both antihypertensive drugs i.e. Nebivolol and metoprolol by comparing there safety accuracy by evaluating which of the two drugs is more safe for the hypertension patient.*

**Keywords:** Hypertension, Pharmacoeconomics, Cost-effectiveness analysis, Cost-effectiveness utilisation in heart failure patient a clinical practice, Beta-blockers, Metoprolol, Nebivolol

## 1. Introduction

Hypertension comprises a noteworthy infection weight to the general public, both as far as the wellbeing related repercussions just as monetary expenses brought about because of dismalness and the combined expense of medication treatment. In reality, it is helpful to have the chance to think about the fitting utilization of antihypertensive medications to educate and manage clinical practice. To assess the adherence of medications remedies in clinical work on as indicated by predefined models of consideration, a progression of pointers quantifiable in connection to explicit conditions have been created. This work presents four pointers: the primary identified with the utilization of medications following up on the renin-angiotensin framework in patients at high cardiovascular hazard; the second identified with the utilization of angiotensin II adversaries with lapsed patent; the third related the infrequent solution of antihypertensive medications; and the fourth on the adherence to treatment with antihypertensive medications. Hypertension is the rapidly increasing chronic condition which is directly associated with the morbidity and mortality rates worldwide. Mainly, we conclude hypertension as high blood pressure as it's another name. It has many risk factors associated with it like: heart disease, stroke and even it can lead to death. We can say that hypertension and heart diseases today is the worldwide health concern. The WHO (world health organisation) inspections have concluded that the growing food industries have widely impacted the human diet worldwide. Today, everyone is consuming the diet which includes the large amount of salt in it, which is somehow the

major cause for the hypertension. every young to the old aged person today is suffering from the risk factors associated with the hypertension .one of the other causes that are been seen for hypertension is stress. Our body produces a large amount of hormones. Thus, when we are in stress our hormones are affected rapidly. Thus, in a stressful situation our hormones are more prone cause rapid increase in blood pressure by rapidly increasing the heart beats and blood vessels narrowed also, if we react to our stress in a wrong way like:

- 1) Consumption of alcohol.
- 2) Smoking.
- 3) Eating very unhealthy diet or meals.

These methods for controlling stress may cause serious life threatening by increasing blood pressure that may adversely affect the heart rate. Reducing stress in a good effective manner may somehow help reducing the blood pressure problems .healthy methods for curing blood pressure due to stress involves:

- 1) Meditation.
- 2) Exercises.
- 3) Yoga.
- 4) Plenty of sleep.

## 2. Literature Review

Hypertension results in increasing heart beat rate twice or thrice time than the normal heart beat rate .During high blood pressure ,our heart beats becomes faster and thus narrow down the blood streaming vessels Which slows down the rate of oxygen towards the heart and therefore ,

can cause death. As per the Registrar General of India and Million Death Study investigators (2001-2003), CVD was the largest cause of deaths in males (20.3%) as well as females (16.9%) and lead to about 2 million deaths annually. In India, 23.10% men and 22.60% women over the age of 25 years suffer from hypertension. In Mumbai, India, on 25th November 2018, cardio logical society of India (CSI), inspected that ,one out of the five adults is suffering from the high blood pressure. It was inspected that the high blood pressure trigger the Indian Population largely than he western population. Thus, currently today youngsters even before the age of 40 suffer from the high blood pressure problems which later over time with no early precautions and the cure of blood pressure cause adverse life threatening issues.

### IN 2017, Hypertension as Wider Cause than diabetes in Indians

As per the data inspected and collaborated by national health profile ((NHP) 2018, there were huge number Indians those who were diagnosed for high blood pressure or hypertension than the Indian with diabetes. Thus, the inspection concluded that hypertension is the biggest concern than diabetes in India. Thus, with the hypertension as the global health concern protective measures are been adopted by the doctors to ensure the safety of the public.

These measures may include:

- 1) Medication: by providing the relevant drug for controlling hypertension.
- 2) Regular exercise.
- 3) Maintaining health diet: avoiding salty food, avoiding fast food.
- 4) No smoking.
- 5) No consumption of alcohol.

### Hypertension Classification

Hypertension is mainly classified in two types:

- 1). Systolic blood pressure.
- 2).diastolic blood pressure.

Some of the individuals suffer from systolic blood pressure and some goes through diastolic blood pressure .Almost everyone today is under the risk of high blood pressure. some people suffer from high blood pressure and they don't even know sometimes what are they suffering from .thus, later with time as blood pressure have no life time cure till now, it goes worst with time .it becomes more high as the time goes on and thus, that can lead to heart attacks and life threats.

### Systolic blood pressure

Systolic blood pressure is identified by the contraction of the heart.

- It is mainly the maximum arterial pressure which occurs due to the contraction of the left ventricle of the heart.
- The first number in the recorded blood pressure measurement 120/80 represents the systolic blood pressure i.e. 120.
- Blood actively pushed the arteries in systolic blood pressure.

### Diastolic blood pressure:

- The diastolic blood pressure is defined as the pressure of the blood inside the arteries when the heart is filling.
- It is usually identified by the extension of the arteries. Of the arteries outwards i.e. the blood push the arteries outwards during diastolic blood pressure.
- The diastolic measurement is the lowest measurement recorded in the blood pressure measurement i.e. 120/80 is the blood pressure measurement than the diastolic blood pressure is measured by 80.

### Pharmacoeconomics

Economics is said to be something that satisfy the unlimited wants of individuals. Thus, Pharmacoeconomics is the branch of health economics which compares value of drug with another .it can also be defined as balancing cost and consequences of pharmaceutical therapies and services. It is the challenge for the professionals. Pharmacoeconomics is the discipline that place value on drug therapy. This field evaluates the behaviour of individuals, marks and Market. It focuses mainly on the cost and the consequences of the drug therapies. It focuses on the quality of life of the patient. Pharmacoeconomics helps in making the decisions those are appropriate and thus are well defined and are all the way safe for the humans. The combination of both the costs and the consequences helps in the decision making. Pharmacoeconomics in India has played a very vital role since years helping in:

- 1) Ensuring the quality of drugs to the individuals.
- 2) Ensuring the safety of the drug for human use.
- 3) Ensuring the efficacy of the drug.

The current healthcare environment requires the evaluation of both the cost and the benefits while conducting the clinical trial. pharmacoeconomics is further classified as:

- 1) Cost benefit analysis: it is related to the advantages of both the costs and the consequences in the monetary units.
- 2) Cost effectiveness analysis: it helps in finding difference between different type of interventions used for the same purpose. We can say it helps in comparison of costs and consequences two or more different interventions.
- 3) Cost minimisation analysis: it relates the two different outcomes or consequences of two different treatments done by using the minimised costs. i.e. Comparing the costs and consequences of two different drugs used for two different types of interventions.
- 4) Cost utility: The cost utility examination (CUA) is like the cost effectiveness investigation (CEA) to the degree that both at the same time look at the expenses and results of at least two interventions.

### Pharmacoeconomic Weight of Undertreating Hypertension

The pharmacoeconomic weight of under treating hypertension can be characterized as the clinical (number of cardiovascular occasions) and financial (expenses of overseeing cardiovascular occasions) outcomes that would have been maintained a strategic distance from by sufficient control of circulatory strain levels. Future examinations are essential for an increasingly exact measurement of the helpful and financial effect of under treating blood vessel

hypertension in clinical practice (fittingness contemplates) and for progressively exact choice of antihypertensive medications based on the diverse cost-effectiveness profiles distinguished in 'genuine world' setting.

### The Monetary Effect of Hypertension

The human expenses of untreated and insufficiently controlled hypertension are huge. Satisfactory administration of hypertension can be checked by deficiencies in the analysis, treatment, as well as control of hypertension. Thus, pharmacoeconomic and hypertension must go hand on hand so that the public burden for treating hypertension could be reduced.

### 3. Conclusion

By observing various prospective and randomized studies open mark observational examination of cost-effectiveness was observed to think about the expense of:

- Nebivolol
- Metoprolol

in medication innocent past analyzed hypertensive patients. the pharmacoeconomic investigations demonstrates that nebivolol is more cost-effective when compared with metoprolol when the expense per decrease in blood pressure every day is considered. This will help patients economically by using these molecules for treatment for the long term use. it will help the clinicians to make quick decision regarding the treatment of hypertension. According to this investigation, it was discovered that Nebivolol has preferable effectiveness over metoprolol as far as decreasing both systolic just as diastolic pulse. In this investigation. It is clear that nebivolol creates less antagonistic impacts and guarantees a superior personal satisfaction than metoprolol. This examination demonstrates that nebivolol is more financially savvy than expanded discharge metoprolol in the treatment of hypertension. Additionally ,offering an ideal unfavourable impact profile and personal satisfaction. It is essential to regulate drugs that are financially savvy and have negligible unfavourable impacts. This is especially significant in a creating nation like India, where, the huge expense of long haul treatment is frequently a huge obstacle.

### References

- [1] Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 report. *JAMA*. 2003;289:2560–72. [PubMed].
- [2] Carretero OA, Oparil S. Essential hypertension. Part I: Definition and etiology. *Circulation*. 2000;101:329–35. [PubMed].
- [3] Abegunde DO, Mathers CD, Adam T, Ortegón M, Strong K. The burden and costs of chronic diseases in low-income and middle-income countries. *Lancet*. 2007;370:1929–38. [PubMed].
- [4] Neal B, MacMahon S, Chapman N. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ace inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: Results of prospectively designed overviews of randomised trials. *Blood pressure lowering treatment trialists' collaboration. Lancet*. 2000;356:1955–64. [PubMed].
- [5] Ogden LG, He J, Lydick E, Whelton PK. Long-term absolute benefit of lowering blood pressure in hypertensive patients according to the jnc vi risk stratification. *Hypertension*. 2000;35:5396. [PubMed].
- [6] The sixth report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. *Arch Intern Med*. 1997;157:2413–46. [PubMed].
- [7] Chalmers J, Zanchetti A. The 1996 report of a World Health Organization expert committee on hypertension control. *J Hypertens*. 1996;14:929–33. [PubMed].
- [8] <http://www.who.int/heli/economics/costeffectanalysis/en/>.
- [9] <http://www.tools4dev.org/resources/how-to-do-a-basic-cost-effectiveness-analysis/>.
- [10] <https://www.webmd.com/drugs/2/drug-149866/nebivolol-oral/details>.
- [11] <https://www.everydayhealth.com/drugs/metoprolol>.
- [12] <https://www.practo.com/medicine-info/metoprolol-25-mg-tablet-6479>.
- [13] <https://accesspharmacy.mhmedical.com/content.aspx?bookid=462&sectionid=41100767>.
- [14] <https://www.mayoclinic.org/drugs-supplements/metoprolol-oral-route/description/drg-20071141>.
- [15] <https://www.medicalnewstoday.com/articles/150109.php>.
- [16] <https://www.mayoclinic.org/diseases-conditions/high-blood-pressure/in-depth/stress-and-high-blood-pressure/art-20044190>
- [17] <https://www.mayoclinic.org/diseases-conditions/high-blood-pressure/in-depth/stress-and-high-blood-pressure/art-20044190>
- [18] <https://www.escardio.org/The-ESC/Press-Office/Press-releases/One-in-five-young-adults-in-India-has-high-blood-pressure>
- [19] <https://www.downtoearth.org.in/news/health/more-indians-were-diagnosed-with-hypertension-than-diabetes-in-2017-60909>
- [20] <https://www.mayoclinic.org/diseases-conditions/high-blood-pressure/in-depth/high-blood-pressure/art-20046974>
- [21] <http://www.bloodpressureuk.org/BloodPressureandyou/FAQs/Bloodpressurennumbers>
- [22] <https://www.cdc.gov/bloodpressure/measure.htm>
- [23] <https://www.webmd.com/heart-disease/heart-failure/qa/what-is-the-definition-of-systolic-pressure>
- [24] <https://www.verywellhealth.com/high-systolic-blood-pressure-treatment-1764091>
- [25] <https://www.webmd.com/heart-disease/heart-failure/qa/what-is-the-definition-of-diastolic-pressure>
- [26] <https://www.slideshare.net/roohna/pharmacoeconomic-s-22-feb-2018>
- [27] <https://www.inc.com/encyclopedia/costs.html>
- [28] <http://www.economicdiscussion.net/theory-of-cost/different-cost-concepts-an.../7000>
- [29] <https://smallbusiness.chron.com/organizations-costs-categorized-different-ways-37918.html>
- [30] <https://bbamantra.com/types-of-cost/>
- [31] <https://www.ncbi.nlm.nih.gov/pubmed/1621734>
- [32] <https://www.ncbi.nlm.nih.gov/pubmed/12436155>
- [33] <https://www.ncbi.nlm.nih.gov/pubmed/37918>

- [34] <https://bbamantra.com/types-of-cost/>
- [35] <https://www.ncbi.nlm.nih.gov/pubmed/1621734>
- [36] <https://www.ncbi.nlm.nih.gov/pubmed/12436155>
- [37] <https://www.ncbi.nlm.nih.gov/pubmed/11482745>
- [38] <https://www.ncbi.nlm.nih.gov/pubmed/27160719>
- [39] <https://www.ncbi.nlm.nih.gov/pubmed/15362928>
- [40] <https://www.ncbi.nlm.nih.gov/pubmed/17414579>
- [41] <https://vascularcures.org/high-blood-pressure-and-vascular-disease/>
- [42] <http://www.pharmideas.com/pharmacoeconomics>
- [43] <https://www.pharmac.govt.nz/assets/pfpa-2-2.pdf>
- [44] [https://en.wikipedia.org/wiki/Cost-effectiveness\\_analysis](https://en.wikipedia.org/wiki/Cost-effectiveness_analysis)
- [45] <https://onlinelibrary.wiley.com/doi/full/10.1002/hec.3058>
- [46] <https://www.ncbi.nlm.nih.gov/pubmed/7604170>
- [47] <https://www.ncbi.nlm.nih.gov/pubmed/15867026>
- [48] <https://www.ncbi.nlm.nih.gov/pubmed/30899223>
- [49] <https://www.ncbi.nlm.nih.gov/pubmed/28103948>
- [50] <https://jamanetwork.com/journals/jama/article-abstract/409182>
- [51] <https://annals.org/aim/article-abstract/703988/clinician-s-guide-cost-effectiveness-analysis>
- [52] <https://annals.org/aim/article-abstract/2696494/value-based-health-care-meets-cost-effectiveness-analysis>
- [53] <https://www.who.int/choice/description/importance/en/>
- [54] [https://www.who.int/choice/description/compare\\_interventions/en/](https://www.who.int/choice/description/compare_interventions/en/)
- [55] [https://www.who.int/choice/description/need\\_databases/en/](https://www.who.int/choice/description/need_databases/en/)
- [56] <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6347566/>
- [57] <https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/1105639>
- [58] <https://academic.oup.com/bmb/article/96/1/5/300011>
- [59] <https://www.ncbi.nlm.nih.gov/pubmed/26395316>
- [60] <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1497852/>
- [61] [http://www.ijlpr.com/admin/php/uploads/372\\_pdf.pdf](http://www.ijlpr.com/admin/php/uploads/372_pdf.pdf)
- [62] <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225910/>
- [63] [https://journals.lww.com/jhypertension/Fulltext/2019/06000/The\\_global\\_burden\\_of\\_hypertension\\_exceeds\\_14.6.aspx](https://journals.lww.com/jhypertension/Fulltext/2019/06000/The_global_burden_of_hypertension_exceeds_14.6.aspx)
- [64] <https://www.ncbi.nlm.nih.gov/pubmed/23409417>
- [65] <https://www.ncbi.nlm.nih.gov/pubmed/21227486>
- [66] <https://www.ncbi.nlm.nih.gov/pubmed/24996589>
- [67] <https://www.ncbi.nlm.nih.gov/pubmed/11516032>
- [68] [https://journals.lww.com/jhypertension/Fulltext/2016/10000/High\\_blood\\_pressure\\_as\\_a\\_risk\\_factor\\_for\\_incident.18.aspx?WT.mc\\_id=HPxADx20100319xMP](https://journals.lww.com/jhypertension/Fulltext/2016/10000/High_blood_pressure_as_a_risk_factor_for_incident.18.aspx?WT.mc_id=HPxADx20100319xMP)
- [69] <https://www.ncbi.nlm.nih.gov/pubmed/23881955>
- [70] [https://journals.lww.com/jhypertension/Fulltext/2017/09000/Withdrawal\\_of\\_antihypertensive\\_medication\\_\\_\\_\\_a.3.aspx?WT.mc\\_id=HPxADx20100319xM](https://journals.lww.com/jhypertension/Fulltext/2017/09000/Withdrawal_of_antihypertensive_medication____a.3.aspx?WT.mc_id=HPxADx20100319xM)